Quick Answer
Neurogene Inc. reported Diluted EPS of $4.24 per share (loss) for fiscal year 2025.
Neurogene Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.24 | +0.9% |
| 2024 | -$4.28 | -246.1% |
| 2023 | $2.93 | +381.7% |
| 2022 | -$1.04 | +5.5% |
| 2021 | -$1.10 | -71.9% |
| 2020 | -$0.64 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.99 | +16.8% | +5.7% |
| June 30, 2025 | -$1.05 | +3.7% | +2.8% |
| March 31, 2025 | -$1.08 | -8.0% | +9.2% |
| September 30, 2024 | -$1.19 | +96.4% | -9.2% |
| June 30, 2024 | -$1.09 | +95.9% | -9.0% |
| March 31, 2024 | -$1.00 | -284.6% | +96.9% |
| September 30, 2023 | -$32.67 | -2668.6% | -22.5% |
| June 30, 2023 | -$26.68 | -9428.6% | -10161.5% |
- Neurogene Inc. showed an increase of +0.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Neurogene Inc.’s diluted eps has declined by 562.5% (from $0.64 per share (loss) to $4.24 per share (loss)).
- The most recent figure is from Neurogene Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: